AAAAAA

   
Results: 1-25 | 26-27
Results: 1-25/27
GABA AND BRAIN ABNORMALITIES IN SCHIZOPHRENIA
Authors: VANKAMMEN DP PETTY F KELLEY ME KRAMER GL BARRY EJ YAO JK GURKLIS JA PETERS JL
Citation: Dp. Vankammen et al., GABA AND BRAIN ABNORMALITIES IN SCHIZOPHRENIA, PSYCHIATRY RESEARCH-NEUROIMAGING, 82(1), 1998, pp. 25-35
CONFIRMATORY FACTOR-ANALYSIS OF THE WAIS-R IN PATIENTS WITH SCHIZOPHRENIA
Authors: ALLEN DN HUEGEL SG SEATON BE GOLDSTEIN G GURKLIS JA VANKAMMEN DP
Citation: Dn. Allen et al., CONFIRMATORY FACTOR-ANALYSIS OF THE WAIS-R IN PATIENTS WITH SCHIZOPHRENIA, Schizophrenia research, 34(1-2), 1998, pp. 87-94
FURTHER-STUDIES OF ELEVATED CEREBROSPINAL-FLUID NEURONAL CELL-ADHESION MOLECULE IN SCHIZOPHRENIA
Authors: VANKAMMEN DP POLTORAK M KELLEY ME YAO JK GURKLIS JA PETERS JL HEMPERLY JJ WRIGHT RD FREED WJ
Citation: Dp. Vankammen et al., FURTHER-STUDIES OF ELEVATED CEREBROSPINAL-FLUID NEURONAL CELL-ADHESION MOLECULE IN SCHIZOPHRENIA, Biological psychiatry, 43(9), 1998, pp. 680-686
UTILITY OF WAIS-R SHORT FORMS IN SCHIZOPHRENIA
Authors: ALLEN DN HUEGEL SG GURKLIS JA KELLEY ME BARRY EJ VANKAMMEN DP
Citation: Dn. Allen et al., UTILITY OF WAIS-R SHORT FORMS IN SCHIZOPHRENIA, Schizophrenia research, 26(2-3), 1997, pp. 163-172
CHRONIC HALOPERIDOL TREATMENT DOES NOT AFFECT STRUCTURE OF ATTENTION IN SCHIZOPHRENIA
Authors: ALLEN DN GILBERTSON MW VANKAMMEN DP KELLEY ME GURKLIS JA BARRY EJ
Citation: Dn. Allen et al., CHRONIC HALOPERIDOL TREATMENT DOES NOT AFFECT STRUCTURE OF ATTENTION IN SCHIZOPHRENIA, Schizophrenia research, 25(1), 1997, pp. 53-61
CSF NEURONAL CELL-ADHESION MOLECULE (N-CAM) IN SCHIZOPHRENIA
Authors: VANKAMMEN DP POLTORAK M KELLEY ME YAO JK GURKLIS JA PETERS JL HEMPERLY JJ FREED WJ
Citation: Dp. Vankammen et al., CSF NEURONAL CELL-ADHESION MOLECULE (N-CAM) IN SCHIZOPHRENIA, Schizophrenia research, 24(1-2), 1997, pp. 68-69
THE ROLE OF IMMUNE MEASURES IN PSYCHOSIS AND STRESS SENSITIVITY IN SCHIZOPHRENIA
Authors: VANKAMMEN DP MCALLISTER CG KELLEY ME MATHE AA BROWN WA YAO JK GURKLIS JA
Citation: Dp. Vankammen et al., THE ROLE OF IMMUNE MEASURES IN PSYCHOSIS AND STRESS SENSITIVITY IN SCHIZOPHRENIA, Schizophrenia research, 24(1-2), 1997, pp. 69-69
SUBSTANCE-ABUSE AND NEUROCOGNITIVE FUNCTION IN SCHIZOPHRENIA
Authors: ALLEN DN GILBERTSON MW SEATON BE GURKLIS JA BARRY EJ VANKAMMEN DP
Citation: Dn. Allen et al., SUBSTANCE-ABUSE AND NEUROCOGNITIVE FUNCTION IN SCHIZOPHRENIA, Schizophrenia research, 24(1-2), 1997, pp. 95-96
WAIS-R FACTOR STRUCTURE IN SCHIZOPHRENIA
Authors: ALLEN DN HUEGEL SG GURKLIS JA KELLEY ME VANKAMMEN DP
Citation: Dn. Allen et al., WAIS-R FACTOR STRUCTURE IN SCHIZOPHRENIA, Schizophrenia research, 24(1-2), 1997, pp. 96-96
UTILITY OF WAIS-R SHORT FORMS IN SCHIZOPHRENIA
Authors: ALLEN DN HUEGEL SG SEATON BE GURKLIS JA KELLEY ME VANKAMMEN DP
Citation: Dn. Allen et al., UTILITY OF WAIS-R SHORT FORMS IN SCHIZOPHRENIA, Schizophrenia research, 24(1-2), 1997, pp. 96-96
IMPACT OF BENZTROPINE ON WAIS-R PERFORMANCE IN SCHIZOPHRENIA
Authors: HUEGEL SG ALLEN DN GURKLIS JA KELLEY ME VANKAMMEN DP
Citation: Sg. Huegel et al., IMPACT OF BENZTROPINE ON WAIS-R PERFORMANCE IN SCHIZOPHRENIA, Schizophrenia research, 24(1-2), 1997, pp. 109-109
ASSESSMENT AND INTERPRETATION OF NONCOMPLIANCE WITH ORAL HALOPERIDOL
Authors: RADOMSKY ED PEREL JM GURKLIS JA VANKAMMEN DP
Citation: Ed. Radomsky et al., ASSESSMENT AND INTERPRETATION OF NONCOMPLIANCE WITH ORAL HALOPERIDOL, Schizophrenia research, 24(1-2), 1997, pp. 217-217
RELIABILITY AND VALIDITY OF WAIS-R SHORT FORMS IN SCHIZOPHRENIA
Authors: HUEGEL SG ALLEN DN VANKAMMEN DP KELLY ME GURKLIS JA
Citation: Sg. Huegel et al., RELIABILITY AND VALIDITY OF WAIS-R SHORT FORMS IN SCHIZOPHRENIA, Archives of clinical neuropsychology, 12(4), 1997, pp. 340-341
THE ROLE OF IMMUNE MEASURES IN SCHIZOPHRENIC BEHAVIOR
Authors: VANKAMMEN DP MCALLISTER CG KELLEY ME MATHJ AA BROWN WA YAO JK GURKLIS JA
Citation: Dp. Vankammen et al., THE ROLE OF IMMUNE MEASURES IN SCHIZOPHRENIC BEHAVIOR, Biological psychiatry, 41, 1997, pp. 399-399
PREDICTING DURATION OF CLINICAL STABILITY FOLLOWING HALOPERIDOL WITHDRAWAL IN SCHIZOPHRENIA
Authors: VANKAMMEN DP KELLEY ME GURKLIS JA GILBERTSON MW YAO JK CONDRAY R PETERS JL
Citation: Dp. Vankammen et al., PREDICTING DURATION OF CLINICAL STABILITY FOLLOWING HALOPERIDOL WITHDRAWAL IN SCHIZOPHRENIA, Schizophrenia research, 18(2-3), 1996, pp. 2-2
CLINICAL-EVIDENCE THAT GABA IS INVOLVED WITH SCHIZOPHRENIA
Authors: VANKAMMEN DP PETTY F KRAMER GL KELLEY ME YAO JK GURKLIS JA PETERS JL
Citation: Dp. Vankammen et al., CLINICAL-EVIDENCE THAT GABA IS INVOLVED WITH SCHIZOPHRENIA, Schizophrenia research, 18(2-3), 1996, p.
CSF OXYTOCIN-NEUROPHYSIN AND VASOPRESSIN-NEUROPHYSIN IN SCHIZOPHRENIA- RELATIONSHIPS WITH STATE AND TRAIT VARIABLES
Authors: VANKAMMEN DP LEGROS JJ KELLEY ME YAO JK GILBERTSON MW CONDRAY R GURKLIS JA PETERS JL
Citation: Dp. Vankammen et al., CSF OXYTOCIN-NEUROPHYSIN AND VASOPRESSIN-NEUROPHYSIN IN SCHIZOPHRENIA- RELATIONSHIPS WITH STATE AND TRAIT VARIABLES, Schizophrenia research, 18(2-3), 1996, p.
PREDICTING DURATION OF CLINICAL STABILITY FOLLOWING HALOPERIDOL WITHDRAWAL IN SCHIZOPHRENIC-PATIENTS
Authors: VANKAMMEN DP KELLEY ME GURKLIS JA GILBERTSON MW YAO JK CONDRAY R PETERS JL
Citation: Dp. Vankammen et al., PREDICTING DURATION OF CLINICAL STABILITY FOLLOWING HALOPERIDOL WITHDRAWAL IN SCHIZOPHRENIC-PATIENTS, Neuropsychopharmacology, 14(4), 1996, pp. 275-283
PREDICTING HALOPERIDOL TREATMENT RESPONSE IN CHRONIC-SCHIZOPHRENIA
Authors: VANKAMMEN DP KELLEY ME YAO JK GILBERTSON MW GURKLIS JA INOSAKA T SAITO H PETERS JL SATO M
Citation: Dp. Vankammen et al., PREDICTING HALOPERIDOL TREATMENT RESPONSE IN CHRONIC-SCHIZOPHRENIA, Psychiatry research, 64(1), 1996, pp. 47-58
ABNORMAL INCORPORATION OF ARACHIDONIC-ACID INTO PLATELETS OF DRUG-FREE PATIENTS WITH SCHIZOPHRENIA
Authors: YAO JK VANKAMMEN DP GURKLIS JA
Citation: Jk. Yao et al., ABNORMAL INCORPORATION OF ARACHIDONIC-ACID INTO PLATELETS OF DRUG-FREE PATIENTS WITH SCHIZOPHRENIA, Psychiatry research, 60(1), 1996, pp. 11-21
GABA AND THE PATHOPHYSIOLOGY OF SCHIZOPHRENIA - A NEURODEVELOPMENTAL PERSPECTIVE
Authors: VANKAMMEN DP PETTY F KELLEY ME KRAMER GL YAO JK GURKLIS JA PETERS JL
Citation: Dp. Vankammen et al., GABA AND THE PATHOPHYSIOLOGY OF SCHIZOPHRENIA - A NEURODEVELOPMENTAL PERSPECTIVE, Biological psychiatry, 39(7), 1996, pp. 26-26
PREDICTING HALOPERIDOL TREATMENT RESPONSE IN CHRONIC-SCHIZOPHRENIA
Authors: VANKAMMEN DP KELLEY ME YAO JK GILBERTSON MW GURKLIS JA INOSAKA T PETERS JL
Citation: Dp. Vankammen et al., PREDICTING HALOPERIDOL TREATMENT RESPONSE IN CHRONIC-SCHIZOPHRENIA, Schizophrenia research, 15(1-2), 1995, pp. 72-73
PREDICTION OF RELAPSE RISK OVER TIME FOLLOWING HALOPERIDOL WITHDRAWALIN SCHIZOPHRENIA
Authors: VANKAMMEN DP KELLEY ME GURKLIS JA GILBERTSON MW YAO JK PETERS JL
Citation: Dp. Vankammen et al., PREDICTION OF RELAPSE RISK OVER TIME FOLLOWING HALOPERIDOL WITHDRAWALIN SCHIZOPHRENIA, Schizophrenia research, 15(1-2), 1995, pp. 73-73
BEHAVIORAL VS BIOCHEMICAL PREDICTION OF CLINICAL STABILITY FOLLOWING HALOPERIDOL WITHDRAWAL IN SCHIZOPHRENIA
Authors: VANKAMMEN DP KELLEY ME GURKLIS JA GILBERTSON MW YAO JK PETERS JL
Citation: Dp. Vankammen et al., BEHAVIORAL VS BIOCHEMICAL PREDICTION OF CLINICAL STABILITY FOLLOWING HALOPERIDOL WITHDRAWAL IN SCHIZOPHRENIA, Archives of general psychiatry, 52(8), 1995, pp. 673-678
BEHAVIORAL VS BIOCHEMICAL PREDICTION OF RELAPSE FOLLOWING HALOPERIDOLWITHDRAWAL IN SCHIZOPHRENIA
Authors: VANKAMMEN DP KELLEY ME GURKLIS JA GILBERTSON MW PETERS JL
Citation: Dp. Vankammen et al., BEHAVIORAL VS BIOCHEMICAL PREDICTION OF RELAPSE FOLLOWING HALOPERIDOLWITHDRAWAL IN SCHIZOPHRENIA, Schizophrenia research, 11(2), 1994, pp. 116-116
Risultati: 1-25 | 26-27